Next Steps in Studying Bromelain-based Enzymatic Debridement on Biofilm and Microbial Loads
In this interview, Dr. Robert J. Snyder provides insight into future plans to further the results of an open phase 2 study assessing the safety, efficacy, and pharmacologic effects of bromelain-based enzymatic debridement product on biofilm and microbial loads in patients with diabetic foot ulcers and venous leg ulcers. Study data were presented in poster format at the 2022 Symposium on Advanced Wound Care (SAWC) Fall.
This is part 2 of a 2-video interview. The first video can be found here.
Transcript
Good morning. My name is Dr. Robert Snyder. I'm the dean and professor of clinical research at Barry University School of Podiatric Medicine. Going forward, what is it that we're going to do to ensure that these results of this small sample size study will be continued? We're now in the process of formulating a phase three trial on venous leg ulcers, and within that study, we are strongly considering looking at biofilm and bioburden as secondary influence.
